As a CRO that specialized in preclinical drug testing, we are required to get multiple blood samples from miniature pigs efficiently and with as little stress to our animals and technicians as possible. Modified Rat Vascular Access ButtonsTM seems to offer the perfect solution. Since 2019, we have surgically implanted buttons in 12 male Göttingen miniature pigs with double (N=11)or single(N=1) channel buttons. Double channel buttons had one PinPortTM used for dosing (white) and one for bleeding (red). Here we present the results of our work.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Frontage's Chris Ryan shares experiences and stories, as well as suggestions for how to set up a successful IND approach. We hope you will find our discussion insightful and help you avoid unexpected surprises in your IND-directed studies.
Chris Ryan is Senior Director of Business Development with Frontage Laboratories, Inc. supporting non-clinical safety and toxicology and drug metabolism and pharmacokinetics (’DMPK’) for pharma and biotech clients’ drug development programs. Mr. Ryan has worked for several Contract Research Organizations in drug development for over 18 years. As a former project manager for IND-directed programs, he has helped dozens of companies work through the complexities of pre-clinical safety and toxicology programs.
Intraperitoneal (IP) dose administration is the preferred method of dosing in the treatment of certain cancers as well as for peritonitis. Unfortunately, replicating IP administration in dogs in order to evaluate drug toxicity has posed multiple, serious challenges, rendering the approach unworkable in the laboratory. It is possible, however, to overcome these challenges by using a modified catheter with an access port to administer the investigational product. Frontage Labs has successfully applied this technique in dosing dogs as part of a study of a chemotherapy drug for ovarian cancer, demonstrating the viability of this method.
In this paper, we provide practical advice on how to usher a small molecule through preliminary toxicology testing and derive information required to design IND-enabling studies. Indeed, with a rigorous exploratory toxicity program, sponsors can mitigate the risk of unexpected challenges and optimize the Good Laboratory Practice (GLP) study plan.